中

Pharmaceutical Development

Chemical synthesis is currently the most widely used method for developing anticancer drugs. By analyzing, improving, and synthesizing the structure of the compound, a more effective anti-cancer drug is ultimately obtained. It can be divided into two methods: chemical modification based on existing drugs and finding active ingredients from natural substances.

Pharmaceutical Development

Chemical synthesis is currently the most widely used method for developing anticancer drugs. By analyzing, improving, and synthesizing the structure of the compound, a more effective anti-cancer drug is ultimately obtained. It can be divided into two methods: chemical modification based on existing drugs and finding active ingredients from natural substances.
The biotechnology method utilizes biological systems to manufacture drugs, which do not pollute the environment and have strong flexibility in modifying the structure of drugs. Although the cost is high and the production speed is slow, the development potential is enormous.



Innovative Pipeline

Treatment field
  • Therapy area
  • Target
  • Discovery
  • PCC
  • IND
  • Phase I
  • Phase II
  • Phase III
  • Parter
  • Parter rights
Invasive Fungal Infection
  • SG1001 (Oral)
  • DHODH
  •  
  •  
  •  
  •  
  •  
  •  
  • the Greater China region
  • SG1001 (Injection)
  • DHODH
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • SG5035 (Injection)
  • β-(1,3)-D-Glucan Synthase
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • SG5035 (Oral)
  • β-(1,3)-D-Glucan Synthase
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Hypercholesterolemia
  • SG3
  • PCSK9
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Solid Tumor
  • SG834
  • KIF18A
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • SG5
  • PRMT5-MTA
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  

Therapeutic Area and the Unmet medical need

Based on the latest literature reports, there are still several unmet needs in the clinical treatment of the three major indications of fungal infections, hyperlipidemia, and solid tumors. The key points are summarized as follows.

  • Fungal Infections

    a. Lack of Broad-Spectrum Antifungal Drugs

    Currently, antifungal drugs in clinical use are primarily classified into echinocandins, polyenes, and triazoles. However, these drugs exhibit relatively limited antifungal spectra. For instance, echinocandins lack antibacterial activity against rare fungi such as mucormycosis and have low intracranial drug concentrations. Additionally, triazoles (except posaconazole) are ineffective against mucormycosis. There is a need to develop novel antifungal drugs with broader spectra, lower toxicity and side effects, targeting both invasive mucormycosis and invasive aspergillosis, while ensuring high bioavailability and low toxicity.

    b. Challenge of Drug Resistance

    The issue of fungal drug resistance is becoming increasingly severe, particularly with azole-resistant Aspergillus fumigatus and Candida parapsilosis. Studies have shown that the resistance rate of azole-resistant Aspergillus fumigatus isolates to azoles can reach up to 4.7%, and multiple CYP51Ap gene substitution types are associated with different azole resistances. There is a need to develop new antifungal drugs and treatment strategies targeting resistant fungi.

  • Hyperlipidemia

    a. High Demand for Lipid Management

    The prevalence of dyslipidemia among Chinese adults is high, and dyslipidemia is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). Enhanced lipid management is crucial to reduce low-density lipoprotein cholesterol (LDL-C) levels, thereby mitigating the risk of aggravation and recurrence of cardiovascular diseases.

    b. Limitations of Therapeutic Drugs

    Statins are the preferred choice for lipid-lowering therapy, but they may not achieve the desired LDL-C levels in some patients. Combination therapy with non-statin drugs (such as PCSK9 inhibitors and cholesterol absorption inhibitors) is necessary to further lower LDL-C levels, albeit with certain limitations and challenges.

    c. Novel Therapeutic Targets

    Research into identifying novel therapeutic targets beyond LDL-C reduction, such as triglycerides, HDL-C, and lipoprotein (a), holds promise for more comprehensive lipid management.

  • Solid Tumors

    a. Limited Treatment Options

    Although there are various treatment modalities for solid tumors, the overall efficacy is limited, especially for patients with advanced or refractory solid tumors. New therapeutic methods and drugs, such as immunotherapy and targeted therapy, need to be developed to improve treatment outcomes and patient survival rates.

    b. Challenges of Immunotherapy

    Despite some progress in solid tumor treatment using immunotherapy, many challenges and unresolved issues remain, including inconsistent efficacy and significant side effects. Further optimization of immunotherapy treatment protocols and dosing strategies is necessary to enhance efficacy and safety.

    c. Exploration of Novel Therapies

    In recent years, various novel therapies, including CAR-T therapy, CAR-NK therapy, and synthetic lethality therapy, are under active development and show promising application prospects. These novel therapies are expected to provide more treatment options and hope for patients with solid tumors, but further clinical validation and optimization are required.



Innovation Research Platform



Oral cyclic peptide platform


Oral cyclic peptide platform: As a peptide drug composed of amino acids, cyclic peptides have minimal toxic side effects and meet the long-term needs of chronic disease patients; Cyclic peptides have higher stability than linear peptides and are not easily hydrolyzed by proteases in the human body. They are easy to make into oral preparations, improve patient compliance, and break the limitations of most peptide drugs that can only be administered by injection.



The 'Tumor Synthesis Lethal' Platform


Synthetic lethal platform: refers to the existence of two partner genes A and B. When one gene A mutates or cannot function, the cell can still survive. However, when an inhibitor of gene B is used to render gene B ineffective, it can lead to cell death. Tumor cells often have a large number of mutations and gene replication errors, which are not present in normal cells. If tumor mutation genes and corresponding synthetic lethal pairing genes are found and targeted, it is possible to "precisely kill" tumor cells containing specific mutations without affecting the expression of normal cellular physiological functions.

For better presentation, please browse vertically on the mobile end